RE: Elsevier plus LexusNexis: profits up for 2008, to over $1.5

["MaryJoan Crowley" <maryjoan.crowley@uniroma1.it>]

Perhaps Elsevier could take a lesson from GlaxoSmithKline and try 
to follow suit.

Andrew Witty, the new head of GlaxoSmithKline, recently announced 
that it would:

-cut its prices for all drugs in the 50 least developed countries 
to no more than 25% of UK and US levels

- reinvest 20% of its profits in the least developed countries

AND

-put any chemicals or processes over which it has intellectual 
property rights that are relevant to finding drugs for neglected 
diseases into a "patent pool", so that they can be explored by 
other researchers.

While limited it does come as a surprise and, as Witty says, 
maybe someone has to move before many people move. Let's hope 
Elsevier takes note.

Sincerely,

Mary Joan Crowley
___________________________________________
Caspur-Ciber

Biblioteca Ingegneria Strutturale e Geotecnica
SAPIENZA University of Rome
via Eudossiana 18 - 00184 ROME Italy

office:  0644585387
e-mail: maryjoan.crowley@uniroma1.it
webpage: http://w3.disg.uniroma1.it/biblioteca/